Loading…
← CockpitCompetitor Analysis › SMTI Sanara MedTech, Inc.Open in the cockpit ↗

Sanara MedTech, Inc.SMTICompetitor analysis, valuation and peers

United States · USD·Health Care›Medical Specialties
Momentum leader 80
Mkt cap
$301M
US dollars, full cap
Free float
53%
of shares outstanding
$/day
$2.12M
20-day average traded
Fwd P/E
59.0×
forward earnings
ROIC−WACC
+13.9 pp
WACC 10.4%
Hurdle
-26 pp
Req g minus delivered
Next earnings
133 days
31 Mar 2027
Close · USD$32.73
1D0.0%
1W+3.5%
1M-1.2%
3M-4.4%
6M+42.3%
YTD+40.2%
1Y+55.3%
ATR %2.5%
Beta0.50
52w lowhigh7.8% off high

What Sanara MedTech does

Employees: 108

Sanara MedTech at a glance

Size Sanara MedTech (SMTI) is a United States Health Care company (Medical Specialties) with a market value of $301M, the 3082nd largest of 3,085 United States companies the cockpit tracks. Shares closed at $32.73 on 18 Nov 2026.

Performance Over six months the shares gained 42.3%, against -20.4% for the median peer and -2.2% for the United States market (cap-weighted) — 3rd highest of 21 in its peer set.

Growth Revenue grew 9.8% over the last twelve months (peer median +2.2%); the operating margin is 10.9% (peer median 7.9%).

Valuation It trades at 59.0× forward earnings against a peer median of 17.1× (3rd most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +46%, so the hurdle is -26 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 13.9 points above its cost of capital (10.4% WACC).

Next results Next results expected around 31 Mar 2027 (exchange calendar; dates can move).

Relative performance

7510012515021 May 202621 Aug 202618 Nov 2026SMTI 138Peer median 80
Six months, rebased to 100: Sanara MedTech against the median of its 20 peers (local-currency closes).

Sanara MedTech financials

Reported figures in USD; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue$112M$103M$86.7M$65.0M$45.8M
Revenue growth—+19%+33%+42%—
Gross profit$102M$92.9M$75.7M$53.5M$37.1M
EBITDA$14.7M$11.8M$4.22M-$3.99M-$9.60M
Net income-$3.02M-$37.6M-$9.66M-$4.30M-$7.94M
Free cash flow$7.29M$2.16M-$229,630-$3.51M-$5.70M
Capital expenditure$131,211$4.65M$229,300$265,246$747,015
Total debt$48.7M$48.2M$32.3M$11.8M$819,224

Quarterly statements and history in the cockpit →

Sanara MedTech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-10%0%68857699966883145889300942300753197A301502377740688273CLTNYDESEMBCVBSN3006536883381609SBSCVSMTI6-month return →1-month return →
Up and to the right = strong over both horizons. Sanara MedTech is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×250×500×750×68857699965889300753197A377740688273CLTNEMBC300653SMTIRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Sanara MedTech is the large dot.

Capital: growth delivered against growth the price implies

-20%0%+20%+40%-25%0%25%50%6883145889300753688468301502377740688273CLTNEMBCVBSN3006536883381609SMTIGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Sanara MedTech is the large dot.

Sanara MedTech competitors and peer comparison

How Sanara MedTech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Sanara MedTech against its 20 peers (data as of 18 Nov 2026)
MeasureSMTIPeer medianRank in peer set
1-month return-1.2%-10.9%5th highest of 21
6-month return+42.3%-20.4%3rd highest of 21
Distance from 52-week high-7.8%-48.0%2nd highest of 21
Revenue growth (TTM)+9.8%+2.2%8th highest of 21
Operating margin10.9%7.9%10th highest of 21
Forward P/E59.0×17.1×3rd most expensive of 13
Growth the price implies (Req g, 7 yrs)19.5%4.4%4th most demanding of 15
Growth delivered (Del g)+45.9%+0.2%highest of 15
Hurdle (Req g minus delivered)-26.4 pp+7.9 pp3rd least demanding of 15
ROIC minus cost of capital+13.9 pp+0.6 pp4th highest of 19
EV / EBITDA22.7×7.8×2nd most expensive of 10
Net debt / EBITDA2.2×1.3×3rd most indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Sanara MedTech SMTIUnited States$301M+42%+10%11%59.0×19.5%+45.9%
Chongqing Xishan Science and Technology 688576.SSChina$301M-40%-23%-29%12.8×n/an/a
Peijia Medical 9996.HKHong Kong$296M-34%+21%-13%292.4×n/an/a
Kontour (Xi'an) Medical Technology 688314.SSChina$291M-46%+8%24%n/a3.1%+16.4%
Japan Eyewear 5889.TJapan$318M-5%+15%32%10.7×-9.4%+20.2%
Shenzhen Bioeasy Biotechnology 300942.SZChina$326M-27%+12%-2%n/an/an/a
Jiangsu Apon Medical Technology 300753.SZChina$326M-34%-15%-10%862.0×20.0%-5.1%
Chemclin Diagnostics 688468.SSChina$327M-24%-10%4%n/a15.8%-4.5%
Tauns Laboratories 197A.TJapan$327M-3%+7%29%16.7×n/an/a
Jiangsu Huayang Intelligent Equipment 301502.SZChina$336M-36%-5%2%n/a34.3%+0.4%
BioNote 377740.KSSouth Korea$337M-14%+12%18%14.4×-15.0%-28.5%
Nanjing Medlander Medical Technology 688273.SSChina$337M-47%-12%8%17.5×35.3%+5.2%
COLTENE CLTN.SWSwitzerland$339M-7%-2%8%25.2×-0.3%-0.7%
YD Bio YDESUnited States$344M+7%+17%-883%n/an/an/a
Embecta EMBCUnited States$345M+99%-8%26%3.8×-19.9%-0.1%
IVF HARTMANN VBSN.SWSwitzerland$352M-2%+7%14%n/a-12.7%-1.3%
Yantai Zhenghai Bio-Tech 300653.SZChina$354M-23%-8%17%36.0×18.4%+4.4%
Beijing Succeeder Technology 688338.SSChina$362M-18%-4%31%16.4×5.7%+3.4%
Star Sports Medicine 1609.HKHong Kong$364M-73%+23%37%n/a-13.1%+36.8%
Stratec SBS.DEGermany$365M+63%-6%4%18.2×19.1%+0.1%
CapsoVision CVUnited States$366M+5%+15%-213%n/an/an/a

Questions

Which companies are Sanara MedTech's closest peers?
The cockpit's peer set: Chongqing Xishan Science and Technology (688576.SS), Peijia Medical (9996.HK), Kontour (Xi'an) Medical Technology (688314.SS), Japan Eyewear (5889.T), Shenzhen Bioeasy Biotechnology (300942.SZ), Jiangsu Apon Medical Technology (300753.SZ), Chemclin Diagnostics (688468.SS), Tauns Laboratories (197A.T).
Is Sanara MedTech expensive compared with its peers?
On forward p/e it trades at 59.0× against a peer median of 17.1×, 3rd most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 20% a year for seven years (Req g). Recent delivered growth is +46%, so the hurdle is -26 pp: the price already allows for a slowdown.
How has Sanara MedTech stock performed?
Over six months to 18 Nov 2026 the shares returned +42.3% against -20.4% for the median peer; over one year +55.3%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.